Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Non-Small Cell Lung Cancer
Featuring perspectives from Dr Edward B Garon, Dr John V Heymach, Dr Corey J Langer, Dr Ticiana Leal, Dr David R Spigel and Dr Helena Yu, including the following topics: Incorporation of Immunotherapeutic Strategies into the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) Introduction (0:00) Strategies to cope with platinum shortages (3:11) Selection of appropriate candidates for neoadjuvant chemoimmunotherapy (5:51) Current clinical role of adjuvant anti-PD-1/PD-L1 antibodies (11:03) Patient selection for and practical implementation of consolidation durvalumab (15:40) Faculty presentation: Dr Heymach (18:05) Contemporary Treatment for Localized or Metastatic NSCLC with an EGFR Mutation Adjuvant osimertinib for EGFR mutation-positive localized NSCLC (29:45) Potential implications of FLAURA2 (35:43) Promising investigational strategies for progressive EGFR-mutant disease (38:15) Sequencing of therapies for metastatic NSCLC with EGFR exon 20 insertion mutations (42:01) Faculty presentation: Dr Yu (46:07) Research Advances Shaping the Current and Future Treatment of Metastatic NSCLC with ALK Rearrangements, ROS1 Rearrangements or RET Fusions Selection of first- and later-line treatment for ALK-rearranged NSCLC (54:36) Role of RET-targeted therapy in current clinical practice (56:53) Selection of therapy for ROS1-positive NSCLC, including for patients with CNS involvement (59:30) Faculty presentation: Dr Langer (1:01:25) Targeting MET, HER2 and KRAS Alterations in NSCLC Current clinical role of trastuzumab deruxtecan in NSCLC (1:16:14) Therapeutic sequencing for NSCLC with KRAS G12C mutations (1:20:41) Management of MET exon 14 mutation-positive NSCLC (1:24:33) Faculty presentation: Dr Spigel (1:29:36) Current Management of Metastatic NSCLC without a Targetable Tumor Mutation Anti-PD-1/PD-L1 antibodies for patients for whom biomarker testing is pending (1:38:48) Selection of first-line therapy for newly diagnosed metastatic NSCLC without a targetable tumor mutation (1:41:13) Role of first-line immunotherapy in PD-L1-negative metastatic NSCLC (1:44:17) Implications of antibiotic use and autoimmune toxicity for checkpoint inhibitor efficacy (1:48:15) Faculty presentation: Dr Garon (1:53:41) Future Directions in the Management of Metastatic NSCLC Future directions in NSCLC: Tumor treating fields and datopotamab deruxtecan (2:04:14) Faculty presentation: Dr Leal (2:13:18) CME information and select publications